ReviewJournal of fungi (Basel, Switzerland)2022
Clinical
Review in Journal of fungi (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pulmonary microbiology and microbiota in adults with non-cystic fibrosis bronchiectasis: a systematic review and meta-analysis.Respiratory research · 2025Pooled it
- Review
- Article
- Effect of transientERJ open research · 2026Article
- Fungal-Associated Endotypes as a Treatable Trait in Bronchiectasis.Pulmonary therapy · 2026Review
- Beyond detection: quantitative interpretation ofFrontiers in cellular and infection microbiology · 2026Article
- Gut microbiota dysbiosis and the gut-lung axis in COPD: mechanisms, clinical relevance, and microbiota-targeted interventions.Frontiers in cell and developmental biology · 2026Review
- Invasive Pulmonary Aspergillosis in Non-Neutropenic Patients: An Evolving Clinical Paradigm.Diagnostics (Basel, Switzerland) · 2025Review
- [Research Progress on the Regulatory Mechanism of Respiratory Microbiota in the Comorbidity of Chronic Obstructive Pulmonary Disease and Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2025Review
- Aspergillus sensitisation & allergic bronchopulmonary aspergillosis in chronic obstructive pulmonary disease: Redefining a treatable trait.The Indian journal of medical research · 2025Article
- Characteristics of pathogenic microorganisms in COPD-related infections: prognostic correlations and implications.Frontiers in cellular and infection microbiology · 2025Observational
- Immune markers for pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: a narrative review.Frontiers in immunology · 2025Review
- The Precision Medicine Era of Bronchiectasis.American journal of respiratory and critical care medicine · 2024Article
- The airway mycobiome and interactions with immunity in health and chronic lung disease.Oxford open immunology · 2024Review
- Clinical utility of metagenomic next-generation sequencing in the diagnosis of invasive pulmonary aspergillosis in acute exacerbation of chronic obstructive pulmonary disease patients in the intensive care unit.Frontiers in cellular and infection microbiology · 2024Article
- Torquetenovirus from bronchoalveolar lavage fluid as a biomarker for lung infection among immunocompromised hosts.Biomarkers in medicine · 2024Article
- Prevalence and predictors of Aspergillus seropositivity and chronic pulmonary aspergillosis in an urban tertiary hospital in Sierra Leone: A cross-sectional study.PLoS neglected tropical diseases · 2023Article
- Interactions between the lung microbiome and host immunity in chronic obstructive pulmonary disease.Chronic diseases and translational medicine · 2023Review
- Detection of Multiple Respiration Patterns Based on 1D SNN from Continuous Human Breathing Signals and the Range Classification Method for Each Respiration Pattern.Sensors (Basel, Switzerland) · 2023Article
- The Fungal and Bacterial Interface in the Respiratory Mycobiome with a Focus onLife (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Pulmonary mycoses remain a global threat, causing significant morbidity and mortality. Patients with airways disease, including COPD and bronchiectasis, are at increased risks of pulmonary mycoses and its associated complications. Frequent use of antibiotics and corticosteroids coupled with impaired host defenses predispose patients to fungal colonization and airway persistence, which are associated with negative clinical consequences. Notably,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.